Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioabsorbable Vascular Solutions

Division of Abbott Laboratories Inc.

Latest From Bioabsorbable Vascular Solutions

ART: Bucking the Trend in Bioabsorbable Stents

Bioabsorbable stents arouse great enthusiasm among both interventionalists and industry executives, because they have one major advantage over current stents, both bare metal and drug-eluting: they obviate the need for a permanent implant when only a temporary scaffolding effect is needed. Many stent companies are hedging their bets, working on stents that incorporate both drug elution and bioabsorbability--but not Paris-based Arterial Remodeling Technologies, which is arguing that natural healing, not drug therapy, is the best approach to therapeutically active stents.

Biocoatings: Not Just the Icing on the Cake

The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
Medical Device Platform Technologies

Guidant: The New Rules of the Device Game

As it seeks to capitalize on new opportunities in both its CRM and interventional businesses, Guidant also confronts a device industry whose rules are changing. The second of a two-part series.
Medical Device Leadership

Guidant's Loss of Innocence

Since its 1994 spin off, Guidant has built itself into one of the leading cardiovascular device companies through a deft technology innovation. But a series of recent missteps, most visibly in its AAA graft business but most importantly in its drug-eluting stent business, has caused this former start-up to grow up quickly. But Guidant officials counter that the AAA problems will quickly be put behind and that the drug-eluting stent program will emerge a winner, every bit as strong as its traditional bare metal stent business and its currently robust cardiac rhythm management business.
Medical Device Leadership
See All

Company Information

  • Industry
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • John Capek, Pres.
  • Contact Info
  • Bioabsorbable Vascular Solutions
    Blue Bell, PA
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register